<DOC>
	<DOC>NCT00613106</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety of long-term treatment with HZT-501.</brief_summary>
	<brief_title>Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)</brief_title>
	<detailed_description>Subject who have completed the 24-week Treatment Period of Horizon Protocol HZ-CA-301 or HZ-CA-303 without developing an upper gastrointestinal ulcer and who are expected to continue to require daily administration of an NSAID for the next 6 months will receive treatment with the same study medication received while participating in HZ-CA-301 or HZ-CA-303.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Nociceptive Pain</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Expected to continue to require daily administration of an NSAID for at least the coming 6 months. Subject completed the 24week Treatment period of either Horizon Protocol HZCA301 or HZCA303 Subject didn't meet all of the Inclusion and Exclusion Criteria for Horizon Protocol HZCA301 or HZCA303 Subject developed or experienced any of the following while on either HZCA301 or HZCA303 Malignant Disease of the gastrointestinal tract Erosive esophagitis Clinically significant cardiac, renal or hepatic disease Uncontrolled diabetes Positive pregnancy test on Study Day 0 Please note that there are other additional criteria. The study center will determine if you meet all of the criteria.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>